SEC Form 4Coverage since Jul 29, 2026
$VKTX insider trading
Over the last 12 months, Viking Therapeutics insiders reported no purchases and 3 sales totaling $6.3M across SEC Form 4 filings.
- Bought · 12m
- — 0 events
- Sold · 12m
- $6.3M 3 events
- Events · 12m
- 3 Form 4 filings, grouped
- Insiders · 12m
- 3 distinct reporters
- 10b5-1 share
- 0% pre-arranged plans
Side
Price · $VKTX · 12Mvia TradingView
Top insiders · 12m
Mancini MariannaChief Operating Officer1× · $610K
ZANTE GREGChief Financial Officer1× · $710K
Lian BrianPresident & CEO1× · $4.9M
All insider trades
3 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 29, 2026 | Lian BrianPresident & CEO · O·D | ▼ Sale | 148,517 | $33.32 | $4.9M | -5.5% | — |
| Jul 29, 2026 | ZANTE GREGChief Financial Officer · O | ▼ Sale | 21,217 | $33.47 | $710K | -9.1% | — |
| Jul 29, 2026 | Mancini MariannaChief Operating Officer · O | ▼ Sale | 18,217 | $33.47 | $610K | -4.1% | — |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $VKTX feed.